Oncology
🇪🇺 EMA Page 6EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 61–72 of 94 articles
Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO
EMA Cell Therapy Framework: Impact on CAR-T Availability in Europe
Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access
Repertoire Immune Medicines Doses First Patient in RPTR-1-201 Phase 1/2 Trial for Advanced Solid Tumors
Alpha Tau Treats First Patient with Alpha DaRT in European Pancreatic Cancer Trial ACAPELLA
Alpha Tau Treats First European Pancreatic Cancer Patient with Alpha DaRT in ACAPELLA Clinical Trial
Blinatumomab Long-Term Safety Study in Pediatric Leukemia Patients Reaches Final Stage
Pembrolizumab Plus Lenvatinib Shows Promise for Rare Clear Cell Gynecological Cancers in Phase 2 Trial
Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations
RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026
Lung Cancer Therapeutics Market to Hit $142.3 Billion by 2036 as Precision Medicine Drives 11.8% Growth
Ipsen's Ojemda (Tovorafenib) Becomes First Targeted Therapy for Pediatric Brain Tumors in EU